Amneal has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug Application for a generic version of Potassium Chloride oral solution, 20 mEq per 15mL and 40 mEq per 15 mL, and has immediately initiated commercialization activities.
"More than half of the volume we see for this product is in the institutional and long-term care segments," said Andy Boyer, Amneal Executive Vice President of Sales & Marketing. "This indicates its usefulness in settings that treat patients who either require or prefer this oral liquid form."
Potassium Chloride oral solution had annual U.S. sales of approximately $185 million according to IQVIATM for the12 months ending May 2018.